Targeting the MAGED2-TRIM28-FLNC axis overcomes chemoresistance in TNBC via EMT suppression

Qifan Luo, Le Chen, Sai Zhao, Lei Wei, Yihao Tian, Jingwei Zhang · 2025

Read Targeting the MAGED2-TRIM28-FLNC axis overcomes chemoresistance in TNBC via EMT suppression by Qifan Luo, Le Chen, Sai Zhao, Lei Wei, Yihao Tian, Jingwei Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751829.txt.

Description

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor response to chemotherapy. Fewer than 40% of patients achieve a complete pathological response to neoadjuvant chemotherapy, demonstrating the chemoresistance characteristic of TNBC. Here, we analyze proteomic and transcriptomic datasets of TNBC patients treated with neoadjuvant chemotherapy and identify MAGED2 as a critical regulator of chemoresistance.

Catalog record

CREATORQifan Luo, Le Chen, Sai Zhao, Lei Wei, Yihao Tian, Jingwei Zhang
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12751829

Browse the full library · About the Tower of Babel